Trial
NCT01244191
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Daiichi Sankyo
Collaborators
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Condition
Non Squamous, Non-small-cell Lung Cancer
Intervention
Tivantinib
Why stopped
Sponsor decision due to the protocol-defined stopping boundary for futility was met based on the interim OS data.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-04-06